Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBIT (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed EBIT for 13 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 5.96% year-over-year to -$1.1 million, compared with a TTM value of -$6.5 million through Sep 2025, down 30.5%, and an annual FY2024 reading of -$5.8 million, down 21.46% over the prior year.
  • EBIT was -$1.1 million for Q3 2025 at Sunshine Biopharma, up from -$2.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$279631.0 in Q4 2021 and bottomed at -$23.4 million in Q4 2022.
  • Average EBIT over 5 years is -$2.3 million, with a median of -$1.2 million recorded in 2022.
  • The sharpest move saw EBIT plummeted 8255.16% in 2022, then skyrocketed 94.92% in 2023.
  • Year by year, EBIT stood at -$279631.0 in 2021, then tumbled by 8255.16% to -$23.4 million in 2022, then surged by 94.92% to -$1.2 million in 2023, then plummeted by 71.64% to -$2.0 million in 2024, then soared by 46.68% to -$1.1 million in 2025.
  • Business Quant data shows EBIT for SBFM at -$1.1 million in Q3 2025, -$2.1 million in Q2 2025, and -$1.3 million in Q1 2025.